Skip to main content
See details

Reimbursement summary for angioplasty of arteries of lower extremities

This post presents an extract from our reimbursement analysis for angioplasty of arteries lower extremities using plain and drug-coated balloons (DCBs) for peripheral artery disease in England, France and Germany. Plain balloon angioplasty is reimbursement via DRG solely and DCBs are reimbursement via combination of DRG and add-on reimbursement.
See details

Ongoing assessment of transcatheter mitral valve implantation system in Norway in August 2019

Norway established in 2013 a framework for the introduction of innovations into the health care system through either a national or hospital-based health technology assessment. This framework is called the “New Method.”

Within this framework, all innovations should undergo HTA before being funded. If the method concerns only one or two hospitals, the assessment shall be initiated by clinicians and ran at the hospital level. The final report is disseminated via a mini-HTA database. If the method is of national concern, it undergoes Single Technology Appraisal at national level followed by the funding decision by the group of payers (Decision Forum, Beslutningsforum).

In August of 2019, the mini-HTA for Tendyne transcatheter mitral valve implantation (TMVI) system was initiated by Oslo University Hospital. The finalized assessment will be published in the National Database for Mini-Method Assessments.

See the full details in Norwegian here.

Subscribe to our newsletter delivered every second week not to miss important reimbursement information.